In this sense, druggable epigenetic therapies specifically designed to modulate the GBM AngioMatrix signature may emerge as promising targets for new approaches against this malignancy given that iHDAC treatment led to a significant decrease in the abundance of ADAM10 and to the absence of ADAM15 from GBM secretome. The gene discussed is ADAM15; the disease is glioblastoma.